Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic CancerGlobeNewsWire • 10/19/26
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong BuyZacks Investment Research • 10/16/26
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced TherapiesGlobeNewsWire • 09/22/26
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerZacks Investment Research • 06/26/26
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/20/26
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/18/26
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/18/26
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to KnowZacks Investment Research • 01/21/26
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?Zacks Investment Research • 01/07/26
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic CancerGlobeNewsWire • 01/05/26
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/14/25
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual MeetingGlobeNewsWire • 11/03/25
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 08/28/25
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed LymphomaGlobeNewsWire • 08/26/25
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewsWire • 07/30/25
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with LymphomaGlobeNewsWire • 06/17/25
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with LymphomaGlobeNewsWire • 05/20/25
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell TherapiesGlobeNewsWire • 05/19/25